타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lifileucel (Amtagvi, LN-144, tumor infiltrating lymphocyte) Iovance Biotherapeutics·Polyclonal tumor neoantigens (TIL) 47 trials | |
|---|---|---|
Overview Program | Opdivo (nivolumab) | Amtagvi (lifileucel) |
Overview Company | Bristol Myers Squibb | Iovance Biotherapeutics |
Overview Modality | ANTIBODY | CGT |
Overview Target | PD-1 | Polyclonal tumor neoantigens (TIL) |
Overview Indication | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | Unresectable or metastatic melanoma after PD-1 blockade |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | Polyclonal recognition of private neoantigens instead of one engineered receptor, so it does not depend on a single shared target. |
Positioning Known limitation | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | Antigen presentation loss (B2M/HLA), TIL exhaustion, and a hostile tumor microenvironment. |
Positioning Development positioning | — | Post-IO salvage |
MoA Mechanism | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Autologous TILs already primed against the patient's tumor are expanded to therapeutic numbers, reinfused after lymphodepletion to clear regulatory cells and cytokine sinks, then supported with IL-2. |
MoA Biomarker | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Tumor mutational burden and baseline tumor burden correlate with response; no required companion diagnostic. |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | — |
Toxicology Animal (cat.) | NHP | — |
Toxicology Major finding | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary and renal impairment, and internal hemorrhage. Most toxicity comes from lymphodepletion and IL-2, not the TILs themselves. |
Toxicology CRS | N/A (checkpoint inhibitor) | Uncommon compared with CAR-T |
Clinical Safety signal | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary and renal impairment, and internal hemorrhage. Most toxicity comes from lymphodepletion and IL-2, not the TILs themselves. |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lifileucel (Amtagvi, LN-144, tumor infiltrating lymphocyte) Iovance Biotherapeutics·Polyclonal tumor neoantigens (TIL) 47 trials | |
|---|---|---|
Overview Program | Opdivo (nivolumab) | Amtagvi (lifileucel) |
Overview Company | Bristol Myers Squibb | Iovance Biotherapeutics |
Overview Modality | ANTIBODY | CGT |
Overview Target | PD-1 | Polyclonal tumor neoantigens (TIL) |
Overview Indication | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | Unresectable or metastatic melanoma after PD-1 blockade |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | Polyclonal recognition of private neoantigens instead of one engineered receptor, so it does not depend on a single shared target. |
Positioning Known limitation | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | Antigen presentation loss (B2M/HLA), TIL exhaustion, and a hostile tumor microenvironment. |
Positioning Development positioning | — | Post-IO salvage |
MoA Mechanism | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Autologous TILs already primed against the patient's tumor are expanded to therapeutic numbers, reinfused after lymphodepletion to clear regulatory cells and cytokine sinks, then supported with IL-2. |
MoA Biomarker | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Tumor mutational burden and baseline tumor burden correlate with response; no required companion diagnostic. |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | — |
Toxicology Animal (cat.) | NHP | — |
Toxicology Major finding | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary and renal impairment, and internal hemorrhage. Most toxicity comes from lymphodepletion and IL-2, not the TILs themselves. |
Toxicology CRS | N/A (checkpoint inhibitor) | Uncommon compared with CAR-T |
Clinical Safety signal | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary and renal impairment, and internal hemorrhage. Most toxicity comes from lymphodepletion and IL-2, not the TILs themselves. |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
추천 비교
추천 비교